Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations 
– an opportunity for VCs? 

For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has conducted an in-depth analysis of the cardiovascular landscape in Europe.  

 In our recent study (https://bit.ly/3VmOK1M) we demonstrated that investments in cardiovascular diseases historically have had a high loss/success ratio. Moreover, a report from BIO (QLS Advisors) found that cardiovascular drug development has one of the longest development durations from phase I to NDA approval (mean 11.5 years). 

Does this indicate that cardiovascular investment cases are less attractive for VCs? 
– Not necessarily.  

Key findings from our analysis suggest that there may be hidden opportunities in cardiovascular subpopulations. We identified two populations that lack therapeutic approaches and at risk of rapid disease progression. 

 – Recurrent ischemia despite best care (3% of STEMIs). 5-year mortality rate: 50%. 

– Advanced atherosclerosis despite absence of modifiable cardiovascular risk factors (15-30% of STEMIs). 20% higher mortality compared to patients with conventional risk factors.  

With high event rates and recurrent disease, these populations have a clear unmet medical need and offer enhanced opportunity to investigate underlying pathophysiology.  

From a VC perspective, could investigations in these populations help to accelerate drug discovery and execution of clinical trials? Let us know what you think or whether you see other ‘hidden’ opportunities in cardiovascular disease! 

Reference: 

– Clinical Development Success Rates and Contributing Factors 2011-2022. Report from Biotechnology, Innovation, Organization and Quantitative Life Sciences. February 2021, Informa UK Ltd. 

– Mortality and Cardiovascular Outcomes in Patients Presenting with Non-ST Elevation Myocardial Infarction Despite No Standard Modifiable Risk Factors: Results From the SWEDEHEART Registry. Figtree et al, Journal of the American Heart Association, July 2022. 

– Characteristics and Outcomes of Early Recurrent Myocardial Infarction After Acute Myocardial Infarction. Nair et al, Journal of the American Heart Association, August 2021. 

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...

Sunstone Life Science Ventures is looking for a Student Assistant

No longer accepting applications We are looking for a student to join our team for approximately 8 hours a week. As part of the team, you will play a pivotal role in the management of our deal flow, which lies in the order of 400-500 opportunities every year....

Sunstone announce new investment in immuno-oncology company STipe Therapeutics

Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first class drugs modulating the STING pathway.

Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia

Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia...

5 latest articles

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?  For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...

Why do VC’s not cut losses in time?

Why do VC’s not cut losses in time?  A clinical trial is a very expensive experiment for testing a hypothesis, while hoping for a positive outcome. However, if well designed, a negative outcome could increase the potential for a positive outcome in a subsequent trial....

Are some diseases associated with a higher risk of venture capital losses?

Are some diseases associated with a higher risk of venture capital losses?  Before summer we posted a study correlating venture capital losses in drug development with the magnitude of funding of clinical trials. We have used two approaches to find losses: 1)...

Do compromises in clinical trials cause Venture Capital losses?

Do compromises in clinical trials cause Venture Capital losses? In 2020 and 2021 Sunstone looked in depth at drug development venture-backed successes to find usable attributes and learn from the past. We have now turned the analysis up-side down and looked at the...

Who is in the driver’s seat of our industry?

A recent analysis from Pharma Intelligence | Informa 2021 highlights the current trends of pipeline products (top panel). We have subsequently surveyed Sunstone’s incoming deal flow for the same period and noted the correlation for the top 3 categories with oncology...